Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shattuck Labs, Inc. (NASDAQ:STTK) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $3.00.

Several analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, August 14th. Leerink Partners decreased their price objective on shares of Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, August 14th. Wall Street Zen raised Shattuck Labs from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Finally, Wedbush initiated coverage on shares of Shattuck Labs in a report on Monday, September 8th. They set an “outperform” rating and a $4.00 price target for the company.

Insider Buying and Selling at Shattuck Labs

In other Shattuck Labs news, Director Mona Ashiya purchased 6,306,127 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were bought at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the completion of the acquisition, the director owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Orbimed Advisors Llc bought 6,306,127 shares of the business’s stock in a transaction on Monday, August 25th. The shares were bought at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the completion of the acquisition, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 12.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Shattuck Labs

Several institutional investors have recently made changes to their positions in STTK. Turtle Creek Wealth Advisors LLC acquired a new position in Shattuck Labs during the 3rd quarter worth approximately $29,000. Virtu Financial LLC bought a new position in shares of Shattuck Labs during the third quarter valued at about $38,000. Squarepoint Ops LLC bought a new stake in Shattuck Labs in the 3rd quarter worth about $46,000. AQR Capital Management LLC increased its stake in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after buying an additional 31,355 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Shattuck Labs during the 1st quarter worth approximately $50,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK opened at $2.03 on Friday. Shattuck Labs has a 52-week low of $0.69 and a 52-week high of $2.71. The company has a market capitalization of $128.46 million, a P/E ratio of -1.99 and a beta of 1.88. The company has a 50-day simple moving average of $2.06 and a 200 day simple moving average of $1.37.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. The business had revenue of $1.00 million for the quarter. As a group, equities analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current year.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.